Connect with us

Technology

Penumbra, Inc. Reports First Quarter 2025 Financial Results

Published

2 years ago

on

ALAMEDA, Calif., April 23, 2025 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025.

Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income of $39.2 million and adjusted EBITDA1 of $59.6 million or net income margin of 12.1% and adjusted EBITDA margin1 of 18.4% in the first quarter of 2025.

First Quarter 2025 Financial Results
Total revenue increased to $324.1 million for the first quarter of 2025 compared to $278.7 million for the first quarter of 2024, an increase of 16.3%, or 16.9% in constant currency1. The United States represented 79.2% of total revenue and international represented 20.8% of total revenue for the first quarter of 2025. Revenue from the U.S. increased 22.5% while revenue from our international regions decreased 2.5%, or 0.1% in constant currency1. Revenue from sales of our global thrombectomy products grew to $226.5 million in the first quarter of 2025, an increase of 20.7%, or 21.2% in constant currency1 over the same period a year ago, driven primarily by the sales of our U.S. thrombectomy products which increased by 25.0% over the same period a year ago. Revenue from sales of our global embolization and access products grew to $97.6 million for the first quarter of 2025, an increase of 7.3%, or 8.1% in constant currency1 from the same period a year ago, driven primarily by our U.S. embolization and access products which increased by 16.2% from the same period a year ago.

Gross profit for the first quarter of 2025 was $215.9 million, or 66.6% of total revenue compared to $181.1 million, or 65.0% of total revenue, for the first quarter of 2024. The improvement in gross margin was primarily driven by favorable product mix across our regions and productivity improvements. Gross margin is impacted by product mix, regional mix, and production initiatives to support demand and create future efficiencies. As such, with favorable product mix, improvement in productivity, and by leveraging our fixed costs on higher volume of new product sales during the year, our gross margin may be positively impacted in the future.

Total operating expenses and non-GAAP operating expenses were $175.5 million, or 54.2% of total revenue for the first quarter of 2025. This compares to total operating expenses of $169.0 million, or 60.7% of total revenue for the first quarter of 2024, which included $4.8 million in non-recurring litigation related expenses and a $2.4 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition. Excluding the charges noted above, total non-GAAP operating expenses1 were $161.8 million, or 58.1% of total revenue for the first quarter of 2024. R&D expenses were $22.1 million for the first quarter of 2025, compared to $24.6 million for the first quarter of 2024. SG&A expenses were $153.5 million for the first quarter of 2025, compared to $144.4 million for the first quarter of 2024.

Income from operations and non-GAAP income from operations was $40.4 million for the first quarter of 2025, compared to income from operations of $12.1 million for the first quarter of 2024. Excluding $4.8 million in non-recurring litigation related expenses and a $2.4 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, non-GAAP income from operations1 was $19.3 million for the first quarter of 2024.

1See “Non-GAAP Financial Measures” for important information about our use of non-GAAP measures.

Full Year 2025 Financial Outlook
The Company reiterates guidance for total revenue for 2025 to be in the range of $1,340 million to $1,360 million. The Company is increasing guidance for the U.S. Thrombectomy franchise growth to 20% to 21% year over year from 19% to 20% previously. The Company reiterates guidance for gross margin expansion of at least 100 basis points in 2025, to more than 67% for the full year, and operating margin expansion to a range of 13% to 14% of revenue for full year 2025.

Webcast and Conference Call Information
Penumbra, Inc. will host a conference call to discuss the first quarter 2025 financial results after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the “Events and Presentations” section under the “Investors” tab of the Company’s website at: www.penumbrainc.com. The webcast will be available on the Company’s website for at least two weeks following the completion of the call.

About Penumbra
Penumbra, Inc., the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.

Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company uses the following non-GAAP financial measures in this press release: a) constant currency, b) non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted earnings per share (“EPS”) and c) adjusted EBITDA and adjusted EBITDA margin.

Constant Currency. The Company’s constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company’s current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company’s results or business.

Non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:

the effect of the amortization of finite lived intangible assets acquired in connection with the Sixense acquisition over their estimated useful lives;the excess tax benefits associated with share-based compensation arrangements; andnon-recurring litigation related expenses.

Adjusted EBITDA and adjusted EBITDA margin. The Company’s adjusted EBITDA reflects the exclusion from GAAP net income of:

non-cash operating charges such as stock-based compensation and depreciation and amortization;non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes; andnon-recurring litigation related expenses.

Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.

Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, the excess tax benefits associated with share-based compensation arrangements, and expenses related to certain litigation matters that we have determined are not a normal or recurring part of our business, including settlement costs and legal fees. Further, we consider adjusted EBITDA and adjusted EBITDA margin useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding non-cash operating charges such as stock-based compensation and depreciation and amortization, non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes and non-recurring litigation related expenses.

The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.

Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 18, 2025. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Penumbra, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands)

March 31, 2025

December 31, 2024

Assets

Current assets:

     Cash and cash equivalents

$                  376,054

$                  324,404

     Marketable investments

2,794

15,727

     Accounts receivable, net

167,981

167,668

     Inventories

415,863

406,737

     Prepaid expenses and other current assets

37,017

36,589

          Total current assets

999,709

951,125

Property and equipment, net

72,465

62,641

Operating lease right-of-use assets

175,331

177,787

Finance lease right-of-use assets

27,126

28,018

Intangible assets, net

6,469

6,513

Goodwill

166,123

165,826

Deferred taxes

102,355

100,332

Other non-current assets

43,729

40,939

         Total assets

$               1,593,307

$               1,533,181

Liabilities and Stockholders’ Equity

Current liabilities:

     Accounts payable

$                    31,153

$                    31,326

     Accrued liabilities

112,675

112,429

  Current operating lease liabilities

12,510

12,221

  Current finance lease liabilities

2,292

2,369

          Total current liabilities

158,630

158,345

Non-current operating lease liabilities

184,652

187,068

Non-current finance lease liabilities

21,201

21,731

Other non-current liabilities

15,942

15,106

          Total liabilities

380,425

382,250

Stockholders’ equity:

Common stock

39

38

Additional paid-in capital

1,116,746

1,096,732

Accumulated other comprehensive loss

(3,130)

(5,843)

Retained earnings

99,227

60,004

Total stockholders’ equity

1,212,882

1,150,931

Total liabilities and stockholders’ equity

$               1,593,307

$               1,533,181

 

Penumbra, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except share and per share amounts)

Three Months Ended March 31,

2025

2024

Revenue

$                  324,140

$                  278,655

Cost of revenue

108,257

97,516

Gross profit

215,883

181,139

Operating expenses:

Research and development

22,077

24,626

Sales, general and administrative

153,456

144,412

Total operating expenses

175,533

169,038

Income from operations

40,350

12,101

Interest and other income, net

3,508

2,525

Income before income taxes

43,858

14,626

Provision for income taxes

4,635

3,624

Net income

$                    39,223

$                    11,002

Net income per share:

Basic

$                         1.02

$                         0.28

Diluted

$                         1.00

$                         0.28

Weighted average shares outstanding:

Basic

38,562,191

38,717,334

Diluted

39,163,428

39,387,359

 

Penumbra, Inc.

Reconciliation of GAAP Operating Expenses and GAAP Income from Operations to Non-GAAP Operating Expenses and Non-GAAP
Income from Operations1

(unaudited)

(in thousands)

Three Months Ended March 31,

2025

2024

GAAP operating expenses

$            175,533

$            169,038

GAAP operating expenses includes the effect of the following items:

Non-recurring litigation related expenses

—

4,823

Amortization of finite lived intangible assets acquired

—

2,380

Non-GAAP operating expenses

$            175,533

$            161,835

GAAP income from operations

$              40,350

$              12,101

GAAP income from operations includes the effect of the following items:

Non-recurring litigation related expenses

—

4,823

Amortization of finite lived intangible assets acquired

—

2,380

Non-GAAP income from operations

$              40,350

$              19,304

_______________________

1See “Non-GAAP Financial Measures” for important information about our use of non-GAAP measures.

 

Penumbra, Inc.

Reconciliation of GAAP Net Income and GAAP Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS1

(unaudited)

(in thousands, except share and per share amounts)

Three Months Ended

March 31, 2025

Three Months Ended

March 31, 2024

Net income

Diluted EPS

Net income

Diluted EPS

GAAP net income

$             39,223

$                 1.00

$             11,002

$                0.28

GAAP net income includes the effect of the following items:

Non-recurring litigation related expenses

—

—

4,823

0.12

Amortization of finite lived intangible assets acquired

—

—

2,380

0.06

Tax effects on the non-GAAP adjustments above2

—

—

(1,736)

(0.04)

Excess tax benefits related to stock compensation awards

(6,593)

(0.17)

(287)

(0.01)

Non-GAAP net income

$             32,630

$                 0.83

$             16,182

$                0.41

GAAP diluted EPS

$                 1.00

$                0.28

Non-GAAP diluted EPS

$                 0.83

$                0.41

Weighted average shares outstanding used to compute:

GAAP diluted EPS

39,163,428

39,387,359

Non-GAAP diluted EPS

39,163,428

39,387,359

_______________________

1See “Non-GAAP Financial Measures” for important information about our use of non-GAAP measures. 

2For the three months ended March 31, 2024, management used a combined federal and state tax rate of 24.10%, to compute the tax effect of non-GAAP adjustments.

 

Penumbra, Inc.

Reconciliation of GAAP Net Income and GAAP Net Income Margin to Adjusted EBITDA and Adjusted EBITDA Margin1

(unaudited)

(in thousands, except for percentages)

Three Months Ended March 31,

2025

2024

GAAP net income

$          39,223

$          11,002

Adjustments to GAAP net income:

Depreciation and amortization expense

5,015

7,519

Interest income, net

(3,063)

(2,891)

Provision for income taxes

4,635

3,624

Stock-based compensation expense

13,785

13,569

Non-recurring litigation related expenses

—

4,823

Adjusted EBITDA

$          59,595

$          37,646

Revenue

$        324,140

$        278,655

Adjusted EBITDA

$          59,595

$          37,646

GAAP net income margin

12.1 %

3.9 %

Adjusted EBITDA margin

18.4 %

13.5 %

_______________________

1See “Non-GAAP Financial Measures” for important information about our use of non-GAAP measures. 

 

Penumbra, Inc.

Reconciliation of Revenue Growth by Geographic Regions to Constant Currency Revenue Growth1

(unaudited)

(in thousands, except for percentages)

Three Months Ended March 31,

Reported Change

FX Impact

Constant Currency Change

2025

2024

$

%

$

$

%

United States

$          256,860

$          209,644

$         47,216

22.5 %

$                —

$         47,216

22.5 %

International

67,280

69,011

(1,731)

(2.5) %

1,646

(85)

(0.1) %

Total

$          324,140

$          278,655

$         45,485

16.3 %

$           1,646

$         47,131

16.9 %

 

Penumbra, Inc.

Reconciliation of Revenue Change by Product Categories to Constant Currency Revenue Growth1

(unaudited)

(in thousands, except for percentages)

Three Months Ended March 31,

Reported Change

 FX Impact

Constant Currency Change

2025

2024

$

%

$

$

%

Thrombectomy

$          226,544

$         187,703

$         38,841

20.7 %

$              916

$         39,757

21.2 %

Embolization and Access

97,596

90,952

6,644

7.3 %

730

7,374

8.1 %

Total

$          324,140

$         278,655

$         45,485

16.3 %

$           1,646

$         47,131

16.9 %

 

Penumbra, Inc.

Reconciliation of Revenue Change by Product Categories and Geographic Regions to Constant Currency Revenue Growth1

(unaudited)

(in thousands, except for percentages)

Three Months Ended March 31,

Reported Change

 FX Impact

Constant Currency Change

2025

2024

$

%

$

$

%

Thrombectomy

United States

$          187,893

$          150,284

$         37,609

25.0 %

$                —

$         37,609

25.0 %

International

38,651

37,419

1,232

3.3 %

916

2,148

5.7 %

Total Thrombectomy

226,544

187,703

38,841

20.7 %

916

39,757

21.2 %

Embolization and Access

United States

68,967

59,360

9,607

16.2 %

—

9,607

16.2 %

International

28,629

31,592

(2,963)

(9.4) %

730

(2,233)

(7.1) %

Total Embolization and Access

97,596

90,952

6,644

7.3 %

730

7,374

8.1 %

Total

$          324,140

$          278,655

$         45,485

16.3 %

$           1,646

$         47,131

16.9 %

_______________________

1See “Non-GAAP Financial Measures” for important information about our use of non-GAAP measures.

Investor Relations
Penumbra, Inc.
investors@penumbrainc.com 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-first-quarter-2025-financial-results-302436343.html

SOURCE Penumbra, Inc.

Related Topics:
Continue Reading

Technology

Revolune and Concept Life Sciences Partner to Help Customers Transition Multiplex IF Assays to Flexible New Workflows

Published

12 minutes ago

on

October 27, 2026

By

OBERKOCHEN, Germany, Oct. 27, 2026 /PRNewswire/ — Revolune today announced a partnership with Concept Life Sciences to help biopharma and life sciences customers reassess, transfer, and scale multiplex immunofluorescence assays using Revolune’s flexible staining technology, which now supports 4- to 7-plex assays. 

The collaboration addresses a growing market need as customers evaluate alternatives to existing workflows and reconsider how best to support tissue biomarker research. With Revolune now offering 4- to 7-plex assay capabilities, Concept Life Sciences can help customers transfer established assays onto the Revolune platform, preserve valuable panel know-how, and move more easily from existing workflows to flexible, ready-to-use multiplex formats. 

“Many customers are not starting from a blank page — they already have assays, panels, and tissue biomarker strategies they need to preserve while moving toward more flexible workflows,” said Adrian Arechiga, CCO of Revolune. “Concept Life Sciences brings the translational biology, biomarker, and assay development expertise needed to help customers make that transition practically and confidently.” 

Concept Life Sciences is a leading contract research organization serving the global life sciences industry, with capabilities across discovery, development, analytical services, translational biology, biomarker discovery, spatial biology, and end-to-end chemistry. By combining these capabilities with Revolune’s adaptable multiplex immunofluorescence technology, the companies aim to help customers generate decision-ready tissue biomarker insights while reducing the operational burden of assay transfer and implementation. 

The partnership is designed for research teams that want to retain the scientific value of existing workflows while gaining access to a more flexible platform for multiplex staining. Customers can work with Concept Life Sciences to evaluate assay transfer feasibility, optimize panel design, run tissue staining workflows, and connect resulting biomarker data to broader discovery and development programs. 

“We are excited to work with Revolune to support customers who are rethinking how they approach multiplex tissue analysis,” said Adam Davenport, CSO at Concept Life Sciences. “Together, we can help teams transfer existing assays, explore new panels, and apply multiplex immunofluorescence in ways that support meaningful translational decisions.” 

The Concept Life Sciences partnership forms part of Revolune’s broader strategy to build an ecosystem of partners that support adoption across different customer needs — from specialist service execution to assay migration, translational biology, and integrated R&D support.

Meet Revolune and Concept Life Sciences at SITC 2026

Revolune and Concept Life Sciences will both be attending the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 4–8, 2026, in Phoenix, Arizona. 

Meet both teams at SITC at Sundown, a relaxed evening of complimentary drinks, dinner and conversation hosted by Concept Life Sciences on November 6, 6.30-8.30 pm. More information: https://www.conceptlifesciences.com/campaigns/sitc-2026.

About Revolune

Revolune is a life science company dedicated to making multiplex immunofluorescence as accessible and practical as routine tissue analysis. Its reagent technologies help laboratories move rapidly from existing primary antibodies to ready-to-use multiplex kits, simplifying spatial biology workflows and enabling researchers to focus on biological questions rather than assay management. 

About Concept Life Sciences

Concept Life Sciences is a leading contract research organisation (CRO) serving the global life sciences industry. For over 25 years, the company, and its heritage companies, have provided consultative and collaborative drug discovery and development services. Our approach, supported by passionate scientists and world-leading capabilities, enables clients to overcome complex scientific challenges and improves program success rates. The company has successfully helped 29 candidates advance to the clinic.

The company offers sophisticated translational biology services coupled with exceptional end-to-end chemistry capabilities to support drug discovery and development across a range of established and emerging modalities, with the ability to seamlessly integrate capabilities and provide bespoke solutions to address client needs.

Collectively, the company’s high-quality services and commitment to customer service across the drug development pathway enhances efficiency in drug discovery, helping clients advance their drugs to clinic in as little as 32 months, well ahead of the industry average of 60 months.

View original content to download multimedia:https://www.prnewswire.com/news-releases/revolune-and-concept-life-sciences-partner-to-help-customers-transition-multiplex-if-assays-to-flexible-new-workflows-302919466.html

SOURCE Revolune

Continue Reading

Technology

From Global Orders to Global Growth: Financial Infrastructure for Mid-Market Exporters

Published

12 minutes ago

on

October 27, 2026

By

At the 140th Canton Fair, PhotonPay demonstrates how its stablecoin-centric financial operating system helps growing exporters manage cross-border collections, currency conversion and global payments.

HONG KONG, Oct. 27, 2026 /PRNewswire/ — For a growing homewares exporter, a major overseas order brings opportunity, but also an immediate question: how will the business finance production, cover shipping costs and manage cash until the buyer pays?

A furniture manufacturer may need to pay suppliers weeks or months before receiving the final payment. A home décor or festive-goods exporter may be managing several seasonal orders at once, each with different delivery schedules, payment terms and currencies. As the business expands into more markets, tracking incoming payments, converting currencies and paying suppliers becomes increasingly complex.

These are everyday challenges behind international trade. At the second phase of the 140th Canton Fair, themed “Quality Home Life” and featuring furniture, kitchenware, household items, home decorations, gifts and festive products, PhotonPay is highlighting how financial infrastructure can help growing exporters manage these demands as they expand internationally.

Financial Tools for the Next Stage of Growth

Large multinational companies can draw on dedicated treasury teams, established banking relationships and sophisticated systems to manage funds across markets. Smaller businesses may have simpler payment needs. Mid-market exporters occupy a different position: their operations span multiple countries and currencies, while their finance teams often remain lean.

At the same time, production and freight costs must be covered before all customer payments arrive. Receivables may be spread across currencies and accounts, while suppliers expect payment according to their own schedules. Finance teams must track receipts, reconcile invoices and maintain a clear view of available funds.

Across multiple markets and overlapping orders, these tasks can consume significant time and complicate decisions about when and where to deploy cash. Growing exporters need practical tools to coordinate collections, manage funds across currencies and pay counterparties worldwide, without having to build a large treasury function from scratch.

Connecting Fiat and Stablecoin Rails to Global Business

Bank accounts and fiat payment networks remain central to international trade, connecting businesses to local collection methods and established banking relationships. Stablecoins offer an additional way to transfer value across borders, with transactions possible outside conventional banking hours depending on the network and transaction arrangements.

Connecting fiat and stablecoin rails can give businesses more flexibility in managing cross-border funds. For exporters, the practical value lies in connecting the stages of a cross-border financial workflow: receiving customer payments, converting currencies and making funds available for supplier payments and other business expenses.

PhotonPay is built around this connection. As a stablecoin-centric financial operating system, PhotonPay brings together a cross-border financial infrastructure across both fiat and stablecoin rails.

Its multi-asset wallet supports fiat currencies and stablecoins within a unified environment. Local collection capabilities cover 21 currencies, enabling businesses to receive payments in the currencies their customers use. Through integrated on- and off-ramp services, businesses can convert between fiat and stablecoins, while 24/7 foreign exchange allow funds to move across markets at any time. Cross-border payouts in fiat and stablecoins are available across 200+ countries and territories. Card issuing capabilities also allow companies to manage overseas business spending directly from one platform.

These capabilities connect the key stages of cross-border financial operations, and for growing exporters, this provides a more integrated way to manage international payments as their business expands.

PhotonPay also extends its infrastructure to platforms through Embedded Finance. Its APIs enable B2B platforms, marketplaces and other digital businesses to integrate financial capabilities, including accounts, fiat and stablecoin wallets, global payouts and card issuing, into their own products. This allows platforms to build collection, payment and fund management services into existing workflows and extend financial capabilities to their customers.

Financial Infrastructure That Grows With the Business

For mid-market exporters, international growth brings new customers, more markets and greater demands on financial operations. The ability to manage funds across borders needs to keep pace, supporting everything from the next production run to the next supplier payment and the next market entry.

By connecting fiat and stablecoin rails within one financial operating system, PhotonPay helps growing businesses manage cross-border funds with greater flexibility as they scale internationally.

Visit PhotonPay at Area D, Booths DT1714–DT1718, during the 140th Canton Fair.

About PhotonPay

PhotonPay is a stablecoin-powered payment operating system built for global infrastructure. Designed for modern enterprises, PhotonPay enables businesses to send, receive, convert, and settle funds across both fiat and stablecoin rails through a single, compliance-first integration, spanning 200+ countries and territories.

For more information, visit [www.photonpay.com].

Disclaimer

This material is for general informational purposes only and does not constitute legal, regulatory, tax, accounting, or investment advice, nor an offer or solicitation for any product or service. The availability, features, and regulatory treatment of PhotonPay’s products and services may vary depending on the user’s location, business model, and the laws and regulations that apply. Any descriptions of functionality, performance, efficiency, cost savings, or compliance support (including, without limitation, references to “real‑time”, “24/7”, “high‑efficiency”, or “compliant” solutions) are aspirational or forward‑looking in nature. Actual outcomes may differ due to market conditions, technological constraints, and regulatory developments, and PhotonPay makes no express or implied representation, warranty, or guarantee as to the achievement of any particular result.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/from-global-orders-to-global-growth-financial-infrastructure-for-mid-market-exporters-302920151.html

SOURCE PhotonPay

Continue Reading

Technology

Rockwell Automation Unveils Record-Breaking Innovation Lineup at Automation Fair 2026

Published

12 minutes ago

on

October 27, 2026

By

From AI-powered manufacturing and next-generation control to cybersecurity and digital engineering, Rockwell showcases technologies designed to help manufacturers build the future of industrial operations

MILWAUKEE, Oct. 27, 2026 /PRNewswire/ — Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced an expanded product showcase for Automation Fair® 2026. Across the plant floor and enterprise, Rockwell’s latest innovations help manufacturers unlock greater productivity, simplify operations and strengthen resilience in an increasingly complex industrial environment. Together, these technologies demonstrate how AI, automation and digital transformation are reshaping the future of industrial operations.

At Automation Fair 2026, attendees will get an exclusive look at new technologies designed to help manufacturers modernize production, accelerate decision-making and scale innovation with greater confidence. The innovations span Rockwell’s automation and software portfolio showcasing practical applications that address some of the industry’s most pressing operational challenges.

“Production systems today are balancing growth, workforce challenges, cybersecurity threats and the need to adapt faster than ever before,” said Matheus Bulho, senior vice president, software & control, Rockwell Automation. “At Automation Fair 2026, we’re bringing together hardware, software and industrial intelligence in new ways, giving customers the tools to move faster, adapt with confidence and create more resilient and autonomous operations.”

Among the list of record-breaking innovative new technologies being showcased are:

LogixEdge™ Controller, enhancing the power of Logix with new form factors and seamless integration of IT and OT workloads that further amplify Logix’s powerful multidiscipline control and information capabilities, including AI workloads that enable autonomous controlCompactLogix® 5390 Controller, delivering enhanced performance and security with greater scalability for modern production system environments.PointMax™ I/O, a next-generation I/O platform designed to simplify deployment and support high-performance machine applications.Armor™ PowerFlex® 330 Integrated Drive Motor, combining motor and drive functionality in a compact solution to reduce complexity and accelerate installation.EtherNet/IP™ In-cabinet Solution, helping manufacturers simplify what it takes to construct, wire, deploy and manage industrial control systems more efficiently.FactoryTalk® Optix™ Version 1.9 and new OptixPanel™ Pro and PanelView™ Pro graphic terminals, providing expanded visualization capabilities across larger distributed systems, enhanced security and a modern operator experience.FactoryTalk® Conductor™, enabling organizations to orchestrate industrial intelligence and agentic engineering across design, operations and maintenance for their entire operations.FactoryTalk® AssetIQ™, FactoryTalk® Design Workbench™ and FactoryTalk® ResilientEdge™ software, helping customers simplify enterprise OT asset management, streamline engineering and improve resilience of edge deployments.New AI innovations for the Plex Smart Manufacturing Platform™ and AI-powered Quality Management capabilities, bringing practical artificial intelligence to everyday manufacturing workflows.Expanded cybersecurity offerings, including SecureOT™ Platform Managed Services, OT Cybersecurity Assessment Suite, and capabilities designed to support OEMs in building more secure machines from the start

In addition to product announcements, attendees will have the opportunity to experience live demonstrations, engage with Rockwell Automation experts and partners and explore the innovations driving greater productivity, flexibility and resilience across manufacturing.

Registration is now open. Join thousands of industrial professionals at Automation Fair 2026 and be among the first to experience Rockwell’s latest innovations in action. Register today at automationfair.com.

About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 26,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise® to life across industrial enterprises, visit www.rockwellautomation.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rockwell-automation-unveils-record-breaking-innovation-lineup-at-automation-fair-2026-302907266.html

SOURCE Rockwell Automation, Inc.

Continue Reading

Trending